FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308381824> ?p ?o ?g. }

• W4308381824 abstract "<h3>Background</h3> Anticancer immunity relies on the release of tumor antigens and subsequent activation of both the innate and adaptive immune systems. After cytotoxic chemotherapy induces neoantigen release, myeloid checkpoint inhibitors have been shown to help potentiate innate immune cell activity including antigen presentation. CD47, a marker of self, interacts with SIRPa on myeloid immune cells and can be upregulated by cancer cells to evade immune responses. Evorpacept is a high affinity CD47-blocking fusion protein with an inactive Fc region designed to safely enhance standard anticancer therapeutics. Pembrolizumab, a T cell checkpoint inhibitor, represents a standard treatment option for patients with previously untreated recurrent/metastatic (R/M) HNSCC, both as a monotherapy and in combination with 5FU + platinum. Through increased activation of the immune system, the combination of evorpacept + pembrolizumab + 5FU/platinum might have greater anti-tumor activity in R/M HNSCC than standard therapeutic approaches. This combination approach could be especially beneficial to R/M HNSCC patients with low PD-L1 expression, where anti-PD-(L)1 therapy historically has diminished efficacy. The combination of evorpacept + pembrolizumab + 5FU/platinum has undergone preliminary testing in the Phase 1 ASPEN-01 study,¹ demonstrating tolerability and clinical response. In previously untreated patients with R/M HNSCC treated with evorpacept + pembrolizumab + 5FU/platinum regardless of PD-L1 expression, objective responses including complete response were demonstrated. <h3>Methods</h3> ASPEN-04 (figure 1) is an ongoing non-comparative, open-label, randomized Phase 2 global study for patients with metastatic or unresectable recurrent HNSCC who have not yet received first-line treatment. After an initial safety lead-in cohort, ~162 patients will be randomized using a 2:1 allocation to receive evorpacept + pembrolizumab + chemotherapy (5FU + either cisplatin or carboplatin) or pembrolizumab + chemotherapy, regardless of PD-L1 expression. Minimization factors used to randomize patients include geography, PD-L1 combined positive score, and human papilloma virus (HPV) (p16) status. Patients in the evorpacept treatment arm will receive evorpacept 45 mg/kg IV Q3W. All patients will receive pembrolizumab 200 mg IV Q3W (maximum of 35 cycles) and standard administration of 5FU and platinum agents. The co-primary endpoints in this trial are 12-month overall survival rate and objective response rate using RECIST v1.1. Key secondary endpoints include duration of response, progression-free survival, overall survival, and safety. Exploratory endpoints will characterize pharmacodynamic properties. <h3>Acknowledgements</h3> We would like to thank all the participating patients, their families, and site research teams. <h3>Trial Registration</h3> ClinicalTrials. gov identifier, NCT04675333 <h3>Reference</h3> Keun-Wook Lee, Hyun Cheol Chung, Tae Min Kim, <i>et al</i>. Evorpacept (ALX148), a CD47 Myeloid Checkpoint Inhibitor, in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) and with Gastric/Gastroesophageal Cancer (GC); ASPEN-01. Poster presented at: Society for Immunotherapy of Cancer Annual Meeting; November 2021. <h3>Ethics Approval</h3> The study was approved by all participating institutions’ Ethics and/or Review Boards." @default.
• W4308381824 created "2022-11-11" @default.
• W4308381824 creator A5001334189 @default.
• W4308381824 creator A5013623124 @default.
• W4308381824 creator A5021936360 @default.
• W4308381824 creator A5023649992 @default.
• W4308381824 creator A5026878751 @default.
• W4308381824 creator A5027821483 @default.
• W4308381824 creator A5033884558 @default.
• W4308381824 creator A5058657668 @default.
• W4308381824 creator A5065964233 @default.
• W4308381824 creator A5066800365 @default.
• W4308381824 creator A5072284989 @default.
• W4308381824 creator A5075711437 @default.
• W4308381824 creator A5080295544 @default.
• W4308381824 creator A5084847095 @default.
• W4308381824 creator A5084964726 @default.
• W4308381824 date "2022-11-01" @default.
• W4308381824 modified "2023-09-26" @default.
• W4308381824 title "676 A phase 2 study of evorpacept (ALX148) in combination with pembrolizumab and chemotherapy in patients with advanced head and neck squamous cell carcinoma (HNSCC); ASPEN-04" @default.
• W4308381824 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0676" @default.
• W4308381824 hasPublicationYear "2022" @default.
• W4308381824 type Work @default.
• W4308381824 citedByCount "0" @default.
• W4308381824 crossrefType "proceedings-article" @default.
• W4308381824 hasAuthorship W4308381824A5001334189 @default.
• W4308381824 hasAuthorship W4308381824A5013623124 @default.
• W4308381824 hasAuthorship W4308381824A5021936360 @default.
• W4308381824 hasAuthorship W4308381824A5023649992 @default.
• W4308381824 hasAuthorship W4308381824A5026878751 @default.
• W4308381824 hasAuthorship W4308381824A5027821483 @default.
• W4308381824 hasAuthorship W4308381824A5033884558 @default.
• W4308381824 hasAuthorship W4308381824A5058657668 @default.
• W4308381824 hasAuthorship W4308381824A5065964233 @default.
• W4308381824 hasAuthorship W4308381824A5066800365 @default.
• W4308381824 hasAuthorship W4308381824A5072284989 @default.
• W4308381824 hasAuthorship W4308381824A5075711437 @default.
• W4308381824 hasAuthorship W4308381824A5080295544 @default.
• W4308381824 hasAuthorship W4308381824A5084847095 @default.
• W4308381824 hasAuthorship W4308381824A5084964726 @default.
• W4308381824 hasBestOaLocation W43083818241 @default.
• W4308381824 hasConcept C121608353 @default.
• W4308381824 hasConcept C126322002 @default.
• W4308381824 hasConcept C143998085 @default.
• W4308381824 hasConcept C197934379 @default.
• W4308381824 hasConcept C203014093 @default.
• W4308381824 hasConcept C2776530083 @default.
• W4308381824 hasConcept C2776833033 @default.
• W4308381824 hasConcept C2777701055 @default.
• W4308381824 hasConcept C2778375690 @default.
• W4308381824 hasConcept C2780057760 @default.
• W4308381824 hasConcept C2780851360 @default.
• W4308381824 hasConcept C502942594 @default.
• W4308381824 hasConcept C71924100 @default.
• W4308381824 hasConcept C8891405 @default.
• W4308381824 hasConceptScore W4308381824C121608353 @default.
• W4308381824 hasConceptScore W4308381824C126322002 @default.
• W4308381824 hasConceptScore W4308381824C143998085 @default.
• W4308381824 hasConceptScore W4308381824C197934379 @default.
• W4308381824 hasConceptScore W4308381824C203014093 @default.
• W4308381824 hasConceptScore W4308381824C2776530083 @default.
• W4308381824 hasConceptScore W4308381824C2776833033 @default.
• W4308381824 hasConceptScore W4308381824C2777701055 @default.
• W4308381824 hasConceptScore W4308381824C2778375690 @default.
• W4308381824 hasConceptScore W4308381824C2780057760 @default.
• W4308381824 hasConceptScore W4308381824C2780851360 @default.
• W4308381824 hasConceptScore W4308381824C502942594 @default.
• W4308381824 hasConceptScore W4308381824C71924100 @default.
• W4308381824 hasConceptScore W4308381824C8891405 @default.
• W4308381824 hasLocation W43083818241 @default.
• W4308381824 hasOpenAccess W4308381824 @default.
• W4308381824 hasPrimaryLocation W43083818241 @default.
• W4308381824 hasRelatedWork W2768318314 @default.
• W4308381824 hasRelatedWork W2777867648 @default.
• W4308381824 hasRelatedWork W2890431112 @default.
• W4308381824 hasRelatedWork W2963491961 @default.
• W4308381824 hasRelatedWork W3000701650 @default.
• W4308381824 hasRelatedWork W3090002302 @default.
• W4308381824 hasRelatedWork W3198308916 @default.
• W4308381824 hasRelatedWork W4243044039 @default.
• W4308381824 hasRelatedWork W4317612392 @default.
• W4308381824 hasRelatedWork W2401464604 @default.
• W4308381824 isParatext "false" @default.
• W4308381824 isRetracted "false" @default.
• W4308381824 workType "article" @default.